Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice

  • 1.

    Lascar, N. et al. Type 2 diabetes in adolescents and young adults. Lancet Diabetes Endocrinol. 6, 69–80 (2017).

  • 2.

    Edelstein, S. L. et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 46, 701–10 (1997).

  • 3.

    Oussaada, S. M. et al. The pathogenesis of obesity. Metabolism 92, 26–36 (2019).

  • 4.

    Morton, G. J., Meek, T. H. & Schwartz, M. W. Neurobiology of food intake in health and disease. Nat. Rev. Neurosci. 15, 367–378 (2014).

  • 5.

    Beaumont, M. et al. Heritable components of the human fecal microbiome are associated with visceral fat. Genome Biol. 17, 189 (2016).

  • 6.

    Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins. Nature 457, 480–484 (2009).

  • 7.

    Menni, C. et al. Gut microbiome diversity and high-fibre intake are related to lower long-term weight gain. Int. J. Obes. (Lond). 41, 1099–1105 (2017).

  • 8.

    Schwiertz, A. et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 18, 190–5 (2010).

  • 9.

    Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1031 (2006).

  • 10.

    Ussar, S. et al. Interactions between Gut Microbiota, Host Genetics and Diet Modulate the Predisposition to Obesity and Metabolic Syndrome. Cell Metab. 22, 516–30 (2015).

  • 11.

    Cani, P. D. et al. Metabolic Endotoxemia Initiates Obesity and Insulin Resistance. Diabetes 56, 1761–1772 (2007).

  • 12.

    Kübeck, R. et al. Dietary fat and gut microbiota interactions determine diet-induced obesity in mice. Mol. Metab. 5, 1162–1174 (2016).

  • 13.

    Fayfman, M., Flint, K. & Srinivasan, S. Obesity, Motility, Diet, and Intestinal Microbiota-Connecting the Dots. Curr. Gastroenterol. Rep. 21, 15 (2019).

  • 14.

    Ridaura, V. K. et al. Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice Gut Microbiota from Twins Metabolism in Mice. Science (80-.). 341, 1241214 (2013).

  • 15.

    Bäckhed, F. et al. The gut microbiota as an environmental factor that regulates fat storage. PNAS 101, 15718–15723 (2004).

  • 16.

    Andersen, A., Lund, A., Knop, F. K. & Vilsbøll, T. Glucagon-like peptide 1 in health and disease. Nat. Rev. Endocrinol. 14, 390–403 (2018).

  • 17.

    Burcelin, R. & Gourdy, P. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity. Obes. Rev. 18, 86–98 (2017).

  • 18.

    Yusta, B. et al. GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R. Diabetes 64, 2537–49 (2015).

  • 19.

    Koehler, J. A. et al. GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7. Cell Metab. 21, 379–91 (2015).

  • 20.

    Wismann, P. et al. The endogenous preproglucagon system is not essential for gut growth homeostasis in mice. Mol. Metab. 6, 681–692 (2017).

  • 21.

    Bang-Berthelsen, C. H. et al. GLP-1 Induces Barrier Protective Expression in Brunner's Glands and Regulates Colonic Inflammation. Inflamm. Bowel Dis. 22, 2078–2097 (2016).

  • 22.

    Anbazhagan, A. N. et al. GLP-1 nanomedicine alleviates gut inflammation. Nanomedicine Nanotechnology, Biol. Med. 13, 659–665 (2017).

  • 23.

    Drucker, D. J., Erlich, P., Asa, S. L. & Brubaker, P. L. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc. Natl. Acad. Sci. 93, 7911–7916 (1996).

  • 24.

    Tsai, C. H., Hill, M., Asa, S. L., Brubaker, P. L. & Drucker, D. J. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am. J. Physiol. Metab. 273, E77–E84 (1997).

  • 25.

    Cani, P. D. et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58, 1091–1103 (2009).

  • 26.

    Wismann, P. et al. Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice. Physiol. Behav. 192, 72–81 (2018).

  • 27.

    Covasa, M., Stephens, R. W., Toderean, R. & Cobuz, C. Intestinal Sensing by Gut Microbiota: Targeting Gut. Peptides. Front. Endocrinol. (Lausanne). 10, 82 (2019).

  • 28.

    Chambers, E. S. et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut 64, 1744–1754 (2015).

  • 29.

    Tolhurst, G. et al. Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein – Coupled Receptor FFAR2. Diabetes 61, 364–371 (2012).

  • 30.

    Psichas, A. et al. The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int. J. Obes. (Lond). 39, 424–9 (2015).

  • 31.

    Wang, L., Li, P., Tang, Z., Yan, X. & Feng, B. Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment. Nat. Publ. Gr. 6, 1–10 (2016).

  • 32.

    Zhao, L. et al. A glucagon-like peptide-1 receptor agonist lowers weight by modulating the structure of gut microbiota. Front. Endocrinol. (Lausanne). 9, 1–13 (2018).

  • 33.

    Zhang, Q. et al. Structure moderation of gut microbiota in liraglutide-treated diabetic male rats. Exp. Biol. Med. 243, 34–44 (2018).

  • 34.

    Wang, Z. et al. Gut microbiome differences between metformin- and liraglutide-treated T2DM subjects. Endocrinol. diabetes Metab. 1, e00009 (2018).

  • 35.

    Wu, J. et al. Effect of Aging and Glucagon-like Peptide 2 on Intestinal Microbiota in SD Rats. Aging Dis. 9, 566 (2018).

  • 36.

    D'Argenio, V. Human Microbiome Acquisition and Bioinformatic Challenges in Metagenomic Studies. Int. J. Mol. Sci. 19, 383 (2018).

  • 37.

    Nielsen, H. B. et al. Identification and assembly of genomes and genetic elements in complex metagenomic samples without using reference genomes. Nat. Biotechnol. 32, 822–8 (2014).

  • 38.

    Palleja, A. et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat. Microbiol. 3, 1255–1265 (2018).

  • 39.

    Larsen, I. S. et al. Human Paneth cell α-defensin 5 treatment reverses dyslipidemia and improves glucoregulatory capacity in diet-induced obese mice. Am. J. Physiol. Metab. ajpendo. 00019.2019, https://doi.org/10.1152/ajpendo.00019.2019 (2019).

  • 40.

    Tølbøl, K. S. et al. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J. Gastroenterol. 24, 179–194 (2018).

  • 41.

    Henderson, S. J. et al. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes. Obes. Metab. 18, 1176–1190 (2016).

  • 42.

    Barreto-Vianna, A. R. C., Aguila, M. B. & Mandarim-de-Lacerda, C. A. Effects of liraglutide in hypothalamic arcuate nucleus of obese mice. Obesity 24, 626–633 (2016).

  • 43.

    Edgar, R. C. UPARSE: Highly accurate OTU sequences from microbial amplicon reads. Nat. Methods 10, 996–998 (2013).

  • 44.

    Schloss, P. D. et al. Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl. Environ. Microbiol. 75, 7537–7541 (2009).

  • 45.

    Cole, J. R. et al. Ribosomal Database Project: Data and tools for high throughput rRNA analysis. Nucleic Acids Res. 42, 633–642 (2014).

  • 46.

    Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C. & Knight, R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 27, 2194–2200 (2011).

  • 47.

    Wang, Q., Garrity, G. M., Tiedje, J. M. & Cole, J. R. Naïve Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl. Environ. Microbiol. 73, 5261–5267 (2007).

  • 48.

    Morris, E. K. et al. Choosing and using diversity indices: insights for ecological applications from the German Biodiversity Exploratories. Ecol. Evol. 4, 3514–3524 (2014).

  • 49.

    Bray, J. R. & Curtis, J. T. An Ordination of the Upland Forest Communities of Southern Wisconsin. Ecol. Monogr. 27, 326–349 (1957).

  • 50.

    Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).

  • 51.

    Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2013).

  • 52.

    Li, D., Liu, C. M., Luo, R., Sadakane, K. & Lam, T. W. MEGAHIT: An ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph. Bioinformatics 31, 1674–1676 (2015).

  • 53.

    Hyatt, D. et al. Prodigal: prokaryotic gene recognition and translation initiation site identification. BMC Bioinformatics 11, 119 (2010).

  • 54.

    Xiao, L. et al. A catalog of the mouse gut metagenome. Nat. Biotechnol. 33, 1103–1108 (2015).

  • 55.

    Altschul, S. F. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25, 3389–3402 (1997).

  • 56.

    Bates, D., Mächler, M., Bolker, B. M. & Walker, S. C. Fitting Linear Mixed-Effects Models Using lme4. J. Stat. Softw. 67, 251–264 (2015).

  • 57.

    Kaufman, L. & Rousseeuw, P. J. Clustering by Means of Medoids. in 1–12 (1987).

  • 58.

    Huerta-Cepas, J. et al. EGGNOG 4.5: A hierarchical orthology framework with improved functional annotations for eukaryotic, prokaryotic and viral sequences. Nucleic Acids Res. 44, D286–D293 (2016).

  • 59.

    Kultima, J. R. et al. MOCAT: A Metagenomics Assembly and Gene Prediction Toolkit. PLoS One 7, 1–6 (2012).

  • 60.

    Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 27, 29–34 (1999).

  • 61.

    Greiner, T. U. & Bäckhed, F. Microbial regulation of GLP-1 and L-cell biology. Mol. Metab. 5, 753–758 (2016).

  • 62.

    Drucker, D. J., Habener, J. F. & Holst, J. J. Discovery, characterization, and clinical development of the glucagon-like peptides. J. Clin. Invest. 127, 4217–4227 (2017).

  • 63.

    Hildebrandt, M. A. et al. High-Fat Diet Determines the Composition of the Murine Gut Microbiome Independently of Obesity. Gastroenterology 137, 1716–1724. e2 (2009).

  • 64.

    Ley, R. E. et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 102, 11070–11075 (2005).

  • 65.

    Ley, R., Turnbaugh, P., Klein, S. & Gordon, J. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022–1023 (2006).

  • 66.

    Finucane, M. M., Sharpton, T. J., Laurent, T. J. & Pollard, K. S. A taxonomic signature of obesity in the microbiome? Getting to the guts of the matter. PLoS One 9, e84689 (2014).

  • 67.

    Turnbaugh, P. J., Bäckhed, F., Fulton, L. & Gordon, J. I. Diet-Induced Obesity Is Linked to Marked but Reversible Alterations in the Mouse Distal Gut Microbiome. Cell Host Microbe 3, 213–223 (2008).

  • 68.

    Duncan, S. H. et al. Human colonic microbiota associated with diet, obesity and weight loss. Int. J. Obes. 32, 1720–1724 (2008).

  • 69.

    Moreira, G. et al. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice. J. Nutr. Biochem. 62, 143–154 (2018).

  • 70.

    Derrien, M., Belzer, C. & de Vos, W. M. Akkermansia muciniphila and its role in regulating host functions. Microb. Pathog. 106, 171–181 (2017).

  • 71.

    Everard, A. et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. PNAS Microbiol. 110, 9066–9071 (2013).

  • 72.

    Shin, N. et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63, 727–735 (2014).

  • 73.

    Sommer, M. O. Advancing gut microbiome research using cultivation. Curr. Opin. Microbiol. 27, 127–132 (2015).

  • 74.

    Jelsing, J. et al. Liraglutide: short-lived effect on gastric emptying–long lasting effects on body weight. Diabetes. Obes. Metab. 14, 531–538 (2012).

  • 75.

    Gérard, P. Metabolism of Cholesterol and Bile Acids by the Gut Microbiota. Pathogens 3, 14–24 (2013).

  • 76.

    Long, S. L., Gahan, C. G. M. & Joyce, S. A. Interactions between gut bacteria and bile in health and disease. Mol. Aspects Med. 56, 54–65 (2017).

  • 77.

    Just, S. et al. The gut microbiota drives the impact of bile acids and fat source in diet on mouse metabolism. Microbiome 6, 134 (2018).

  • 78.

    Linden, D. R. Hydrogen Sulfide Signaling in the Gastrointestinal Tract. Antioxid. Redox Signal. 20, 818–830 (2014).

  • 79.

    den Hartigh, L. J. et al. Obese Mice Losing Weight Due to trans-10,cis-12 Conjugated Linoleic Acid Supplementation or Food Restriction Harbor Distinct Gut Microbiota. J. Nutr. 148, 562–572 (2018).

  • 80.

    Speakman, J. R. & Mitchell, S. E. Caloric restriction. Mol. Aspects Med. 32, 159–221 (2011).

  • 81.

    Overton, J. M. & Williams, T. D. Behavioral and physiologic responses to caloric restriction in mice. Physiol. Behav. 81, 749–54 (2004).

  • 82.

    Drucker, D. J. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat. Clin. Pract. Endocrinol. Metab. 1, 22–31 (2005).

  • Bookmark the permalink. RSS feed for this post.

    Leave a Reply

    Powered by Blogger.

    Search

    Swedish Greys - a WordPress theme from Nordic Themepark. Converted by LiteThemes.com.